



## Commercial/Healthcare Exchange PA Criteria Effective: May 8<sup>th</sup>, 2019

**Prior Authorization:** Calquence

**Products Affected:** Calquence (acalabrutinib) oral capsule, Calquence (acalabrutinib) oral tablets

**Medication Description:**

Calquence is indicated to treat mantle cell lymphoma (MCL) in adults who have received at least one prior therapy. Calquence inhibits Bruton tyrosine kinase (BTK), which is a signaling molecule with subsequent downstream effects on B-cell proliferation, differentiation, apoptosis, and cell migration.

**Covered Uses:**

1. Treatment of mantle cell lymphoma in adults who have received at least one prior therapy
2. Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

**Exclusion Criteria:**

1. Pediatric patients less than 18 years of age
2. Previous treatment with a BTK inhibitor (Imbruvica)

**Required Medical Information:**

1. Diagnosis
2. History of previous therapy tried/failed
3. Dose and frequency

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** Prescribed by, or in consultation with, an oncologist

**Coverage Duration:** 3 years

**Other Criteria:**

1. **Mantle Cell Lymphoma**
  - A. Patient has a diagnosis of mantle cell lymphoma; **AND**
  - B. Has received at least one prior therapy (chemotherapy, rituximab, Revlimid, etc); **AND**
  - C. Calquence must be used as a single agent
2. **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)**
  - A. Patient has a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)

**References:**

Last Res. September 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

1. Calquence [package insert] Wilmington DE; AstraZeneca; October 2017.
2. Zelenetz AD, Gordon LI, Wierda WG, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines in oncology. B cell lymphomas. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/Bcell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/Bcell.pdf). Accessed December 14, 2017.
3. Micromedex® 2.0 (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/>. Accessed December 14, 2017.
4. Wu J, Zhang M, Liu D. Acalabrutinib: a selective second-generation BTK inhibitor. J Hematol Oncol. 2016; 9:21. doi: 10.1186/s13045-016-0250-9.
5. Calquence (acalabrutinib tablets) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy, Adopted EH criteria, removed Calquence from CCI "Oncology" Policy	All	4/17/19
2	Policy Update	Added continuation coverage duration of 3 years	Coverage Duration	7/1/2019
3	Policy Update	Updated indication to match FDA Label	Covered Uses, Other Criteria	12/12/2019
4	Policy Update	Added Calquence Tablets to Products Affected	Products Affected	9/15/2022